Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

CorMedix (NASDAQ: CRMD) Strengthens Its Commercial Growth Story

Oct 08, 2026 | Team Kalkine
CorMedix (NASDAQ: CRMD) Strengthens Its Commercial Growth Story
Image source: shutterstock

  • CRMD:NASDAQ
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

CorMedix Inc. (NASDAQ: CRMD)

CorMedix Inc. (NASDAQ: CRMD) is a biopharmaceutical company focused on developing and commercializing therapies designed to address infectious and other serious medical conditions, with DefenCath serving as its key commercial product. Its pipeline also includes REZZAYO for potential prophylaxis of invasive fungal disease and DefenCath for the total parenteral nutrition (TPN) indication.

Key Business and Financial Updates:


Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…